transdermal patch, page-2

Well thats about the most Bullish Statement that Dr Esra has put out for a market worth $1.5Billion PA. Go POH!

“The development of our TPM patch has the potential to be a substantial commercial success for Phosphagenics”, said Dr Ogru. Our transdermal patch should increase the amount and duration of oxycodone delivered into the systemic circulation, and could reduce potential opioid abuse, a major consideration for the FDA when reviewing possibly addictive substances such as oxycodone.

In addition, our TPM skin patch should allow us to deliver other opioid based compounds, including morphine and hydromorphone, as well as other products that are targeted for delivery into the systemic circulation, including insulin. Phosphagenics has already completed a human trial that demonstrated that its TPM/insulin formulation safely delivered insulin transdermally into patients with Type 1 diabetes”.